Please assess the completion status of the following clinical trial:

Trial Title: Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Both genders (50%, male). All races and ethnic groups.~* Premenopausal women in the follicular phase, non-lactating, and with a negative pregnancy test. Postmenopausal women on stable dose of or not exposed to hormone replacement for ≥6 months.~* Hematocrit (HCT)≥ 34%, serum creatinine ≤ 1.4 mg/dl, and normal results of serum electrolytes, urinalysis, and coagulation tests. Liver function tests (LFTs) up to 2 times normal~* Stable body weight (±2%) for ≥ 3 months.~* Two or less sessions of strenuous exercise/wk for last 6 months.~Exclusion Criteria:~* Current treatment with drugs known to affect glucose and lipid homeostasis. If the subject has been on a stable dose for the past 3 months, the following agents will be permitted: calcium channel blockers, β-blockers, ACE inhibitors, angiotensin receptor blockers, and statins~* History of allergy to sevelamer.~* Non-steroidal anti-inflammatory drugs or systemic steroid use for more than a week within 3 months.~* Current treatment with anticoagulants (warfarin). Aspirin (up to 325 mg) and clopidogrel will be permitted if these can be held for seven days prior to the biopsy in accordance with the primary physician.~* Use of agents that affect gut flora (e.g. antibiotics, colestyramine, lactulose, PEG) within 3 months.~* History of heart disease (New York Heart Classification greater than grade II; more than non-specific ST-T wave changes on the ECG), peripheral vascular disease, pulmonary disease, smokers.~* Poorly controlled blood pressure (systolic BP\>170, diastolic BP\>95 mmHg).~* Active inflammatory, autoimmune, hepatic, gastrointestinal, malignant, and psychiatric disease.~* History of gastrointestinal surgery or gastrointestinal obstruction within two years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Type2 Diabetes Mellitus - Placebo (Type: PLACEBO_COMPARATOR): Type 2 Diabetes Mellitus subjects will receive maltodextrin (placebo)
- Obese with NGT - Placebo (Type: PLACEBO_COMPARATOR): Obese (BMI = 30-37 kg/m2) normal glucose tolerant (NGT) subjects will receive maltodextrin (placebo)
- Lean with NGT -Placebo (Type: PLACEBO_COMPARATOR): Lean (BMI\< 26 kg/m2) normal glucose tolerant (NGT) will receive maltodextrin (placebo)
- Type2 Diabetes Mellitus - Synbiotic (Type: ACTIVE_COMPARATOR): Type 2 Diabetic subjects will receive synbiotic
- Type2 Diabetes Mellitus - Sevelamer (Type: ACTIVE_COMPARATOR): Type 2 Diabetic subjects will receive sevelamer
- Obese with NGT - Synbiotic (Type: ACTIVE_COMPARATOR): Obese (BMI = 30-37 kg/m2) normal glucose tolerant subjects (NGT) will receive Synbiotic
- Obese with NGT - Sevelamer (Type: ACTIVE_COMPARATOR): Obese subjects (BMI = 30-37 kg/m2) normal glucose tolerant (NGT) will receive Sevelamer
- Lean with NGT - Synbiotic (Type: ACTIVE_COMPARATOR): Lean (BMI\< 26 kg/m2) normal glucose tolerant (NGT) will receive Synbiotic
- Lean with NGT - Sevelamer (Type: ACTIVE_COMPARATOR): Lean (BMI\< 26 kg/m2) normal glucose tolerant (NGT) will receive Sevelamer

Based on this trial design, predict the completion outcome and termination type (if applicable).